References
- 1. Li J, Tuo B. Current and Emerging Approaches for Hepatic Fibrosis Treatment. Gastroenterol Res Pract. 2021 Jul 16;2021:6612892. doi: 10.1155/2021/6612892. PMID: 34326871; PMCID: PMC8310447.10.1155/2021/6612892831044734326871
- 2. Popov Y, Sverdlov DY, Sharma AK, et al. Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice. Gastroenterology 2011;140:1642–1652.10.1053/j.gastro.2011.01.040337413221277850
- 3. Rockey DC, Bell PD, Hill JA. Fibrosis–a common pathway to organ injury and failure. N Engl J Med 2015; 372:1138–1149.10.1056/NEJMra130057525785971
- 4. Massard J, Ratziu V, Thabut D, et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006;44:S19–S24.10.1016/j.jhep.2005.11.00916356583
- 5. Eslam M, McLeod D, Kelaeng KS, et al. IFN-lambda3, not IFN-lambda4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. Nat Genet 2017;49:795–800.10.1038/ng.383628394349
- 6. Popov Y, Sverdlov DY, Bhaskar KR, et al. Macrophagemediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. Am J Physiol 2010;298:G323–G334.10.1152/ajpgi.00394.2009283851620056896
- 7. Chen SH, Huang CL, Chiang IP, et al. Liver fibrosis regression correlates with downregulation in liver angiogenesis in chronic hepatitis C through viral eradication, European Journal of Gastroenterology & Hepatology: September 2021 - Volume 33 - Issue 9 - p 1209-1217.10.1097/MEG.000000000000183332658008
- 8. Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 2000;124:1599–1607.10.5858/2000-124-1599-ROHC11079009
- 9. Lee YA, Friedman SL. Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res 2014;107:23–30.
- 10. Goodman ZD, Stoddard AM, Bonkovsky HL, et al. Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology 2009;50:1738–1749.10.1002/hep.23211370763319824074
- 11. Brian L. Pearlman1,3,4 and Nomi Traub. Sustained Virologic Response to Antiviral Therapy for Chronic Hepatitis C Virus Infection: A Cure and So Much More. Sustained Virologic Response Hepatitis C d CID 2011:52 (1 April) d 889-90010.1093/cid/cir07621427396
- 12. Knop V, Hoppe D, Welzel T, et al. Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy. J Viral Hepat 2016;23:994–1002.10.1111/jvh.1257827500382
- 13. Poynard T, Moussalli J, Munteanu M, et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol 2013;59:675–683.10.1016/j.jhep.2013.05.01523712051
- 14. Lu M, Li J, Zhang T, et al. Serum biomarkers indicate long-term reduction in liver fibrosis in patients with sustained virological response to treatment for HCV infection. Clin Gastroenterol Hepatol 2016;14: 1044–1055.e3.10.1016/j.cgh.2016.01.009572625026804385
- 15. Dhanasekaran R, Sanchez W, Mounajjed T, et al. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. Liver Int 2015;35:2433–2441.10.1111/liv.1289026058570
- 16. Mauro E, Crespo G, Montironi C, et al. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. Hepatology 2018;67:1683–1694.10.1002/hep.2955728960366
- 17. Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology 2006;43:S113–S120.10.1002/hep.2104616447288
- 18. Rockey DC. Noninvasive assessment of liver fibrosis and portal hypertension with transient elastography. Gastroenterology 2008;134:8–14.10.1053/j.gastro.2007.11.05318166342
- 19. Van der Meer AJ, Feld JJ, Hofer H, et al. Risk of cirrhosis related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol 2017; 66:485–493.10.1016/j.jhep.2016.10.01727780714
- 20. Nahon P, Bourcier V, Layese R, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 2017;152:142–156.e2.
- 21. Rossi C, Jeong D, Wong S, et al. Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations. J Hepatol 2019;71:1116–1125.10.1016/j.jhep.2019.07.02131433302
- 22. Hill LA, Delmonte RJ, Andrews B, et al. Treatment of hepatitis C with direct-acting antivirals significantly reduces liver-related hospitalizations in patients with cirrhosis. Eur J Gastroenterol Hepatol 2018;30:1378–1383.10.1097/MEG.000000000000119529975243
- 23. Sun YM, Chen SY, You H. Regression of liver fibrosis: evidence and challenges. Chin Med J (Engl). 2020;133(14):1696-1702.10.1097/CM9.0000000000000835740174132568866